

AMENDMENTS TO THE CLAIMS

Please amend claims 1-2, 7-9 and 15, add claim 18 and cancel claims 3-6, 10-14 and 16-17. With the amendments, claims 1-2, 7-9, 15 and 18 are pending.

This listing of claims will replace all prior versions, and listings of claims in this application.

Listing of Claims:

1. (Currently amended) A method ~~pharmaceutical composition~~ for the treatment and/or prevention of asthma ~~a disease, a disorder and/or a condition caused by expression of a gene controlled by NF- κ B or ets, the~~ comprising the step of administering a composition comprising:

~~at least one~~ an NF- κ B decoy; and

a pharmaceutically acceptable carrier.

2. (Currently Amended) ~~A composition~~ The method according to claim 1, wherein the ~~at least one decoy is an~~ NF- κ B decoy comprises the nucleotide sequence of SEQ ID NO. 13 ~~or a derivative, variant or fragment thereof, and the derivative, variant or fragment thereof has biological activity.~~

3.-6 (Cancelled)

7. (Currently amended) ~~A composition~~ The method according to claim 1, wherein the pharmaceutically acceptable carrier is a hydrophilic polymer.

8. (Currently amended) ~~A composition~~ The method according to claim 1, wherein the pharmaceutically acceptable carrier is a liposome.

9. (Currently amended) ~~A~~ The method according to claim 1,
~~pharmaceutical composition for treatment and/or prevention of a disease, a disorder and/or a~~
~~condition wherein the asthma is caused by eosinophilic abnormality, the composition~~
~~comprising:~~

~~at least one decoy; and~~

~~a pharmaceutically acceptable carrier.~~

10.-14. (Cancelled)

15. (Currently amended) ~~A composition~~ The method according to claim 1-9,
wherein ~~the disease~~ asthma is selected from the group consisting of bronchial asthma,
childhood asthma, allergic asthma, atopic asthma, steroid-resistant asthma (SRA), non-allergic
asthma, intrinsic asthma, extrinsic asthma, aspirin-induced asthma, cardiac asthma, and
infectious asthma.

16.-17. (Cancelled)

18. (New) The method according to claim 2, wherein the NF- κ B decoy
comprises an oligonucleotide having a sequence selected from the group consisting of SEQ ID
NO: 1 and SEQ ID NO: 5.